Cabaletta Bio is forging ahead with rese-cel, a CAR T cell therapy for autoimmune diseases, targeting a 2027 FDA submission. The Philadelphia-based biotech has mapped out an ambitious 2026 roadmap that underscores its commitment to advancing next-generation treatment options.